GALMED PHARMACEUTICALS LTD. (GLMD)
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business